Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients.

[1]  Melanie S. Jefferson,et al.  A Systems Approach to Interrogate Gene Expression Patterns in African American Men Presenting with Clinically Localized Prostate Cancer , 2021, Cancers.

[2]  D. Theodorescu,et al.  An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer , 2021, Nature Communications.

[3]  N. Malats,et al.  An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer , 2021, Nature Communications.

[4]  Jason Zhu,et al.  Genomic analysis of response to bacillus Calmette-Guérin (BCG) treatment in high-grade stage 1 bladder cancer patients , 2021, Translational andrology and urology.

[5]  C. Drake,et al.  Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials , 2019, Clinical Cancer Research.

[6]  Y. Lotan,et al.  Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. , 2019, European urology.

[7]  Jordan H. Creed,et al.  Commercial Gene Expression Tests for Prostate Cancer Prognosis Provide Paradoxical Estimates of Race-Specific Risk , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[8]  Rui Qiao,et al.  S100A16 regulated by Snail promotes the chemoresistance of nonmuscle invasive bladder cancer through the AKT/Bcl-2 pathway , 2019, Cancer management and research.

[9]  E. Compérat,et al.  Microbiota: Bacteriophage diversity in the urinary microbiome , 2018, Nature Reviews Urology.

[10]  A. Jemal,et al.  Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.

[11]  Olivia Alder,et al.  Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency. , 2017, Cancer cell.

[12]  S. Tomlins,et al.  Fibulin-3 promotes muscle-invasive bladder cancer , 2017, Oncogene.

[13]  Simon P. Kim,et al.  Population-based assessment of racial/ethnic differences in utilization of radical cystectomy for patients diagnosed with bladder cancer , 2017, Cancer Causes & Control.

[14]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.

[15]  John D Seigne,et al.  Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. , 2016, The Journal of urology.

[16]  M. L. Calle,et al.  Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. , 2016, Cancer cell.

[17]  Måns Magnusson,et al.  MultiQC: summarize analysis results for multiple tools and samples in a single report , 2016, Bioinform..

[18]  D. Grignon,et al.  Best Practices Recommendations in the Application of Immunohistochemistry in the Bladder Lesions: Report From the International Society of Urologic Pathology Consensus Conference , 2014, The American journal of surgical pathology.

[19]  M. Glickman,et al.  The mechanism of action of BCG therapy for bladder cancer—a current perspective , 2014, Nature Reviews Urology.

[20]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.

[21]  Karim Chamie,et al.  Recurrence of high‐risk bladder cancer: A population‐based analysis , 2013, Cancer.

[22]  D. Grignon,et al.  ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. , 2013, European urology.

[23]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[24]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[25]  Helga Thorvaldsdóttir,et al.  Molecular signatures database (MSigDB) 3.0 , 2011, Bioinform..

[26]  P. Carroll,et al.  Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). , 2011, The Journal of urology.

[27]  W. Lowrance,et al.  Ethnic differences in bladder cancer survival. , 2009, Urology.

[28]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[29]  W. El-Deiry,et al.  Mcl-1: a gateway to TRAIL sensitization. , 2008, Cancer research.

[30]  J. Castle,et al.  expression data: the tissue distribution of human pathways , 2006 .

[31]  R. Dunn,et al.  Gender and geographic influence on the racial disparity in bladder cancer mortality in the US. , 2006, Journal of the American College of Surgeons.

[32]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Richie,et al.  Bladder cancer. Clinical practice guidelines in oncology. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[34]  G. Prout,et al.  Survival experience of black patients and white patients with bladder carcinoma , 2004, Cancer.